COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Flortaucipir PET Imaging in Subjects With FTD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03040713
Recruitment Status : Completed
First Posted : February 2, 2017
Last Update Posted : January 10, 2019
Information provided by (Responsible Party):
Avid Radiopharmaceuticals

Brief Summary:
This study is designed to assess the usefulness of 18F-AV-1451 in Positron Emission Tomography imaging for subjects diagnosed with Frontotemporal Dementia.

Condition or disease Intervention/treatment Phase
Frontotemporal Dementia Drug: 18F-AV-1451 Drug: 18F-AV-45 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: 18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia
Actual Study Start Date : April 11, 2017
Actual Primary Completion Date : October 24, 2018
Actual Study Completion Date : October 24, 2018

Arm Intervention/treatment
Experimental: FTD Subjects
Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or TDP-43 pathology.
Drug: 18F-AV-1451
Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
Other Names:
  • Flortaucipir F18
  • [F-18]T807

Drug: 18F-AV-45
Subjects with no qualifying amyloid scan within three years will receive single IV administration of 370 MBq (10 mCi) of 18F-AV-45 prior to enrollment as a screening assessment
Other Names:
  • Florbetapir F18
  • Amyvid

Primary Outcome Measures :
  1. 18F-AV-1451 tracer uptake measured by regional SUVr [ Time Frame: 75 minutes post dose administration ]
    To estimate SUVr (Standard Uptake Value Ratio) in FTD subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have provided informed consent or have a legally authorized (LAR) provide consent for study procedures
  • Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
  • Can tolerate PET scan procedures

Exclusion Criteria:

  • Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
  • Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause QT prolongation
  • Have history of drug or alcohol dependence within the last year
  • Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity, or not using reliable contraception
  • Have history of relevant severe drug allergy or hypersensitivity
  • Have received an investigational medication under FDA IND protocol within 30 days of planned imaging session
  • Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
  • Possess PET scan evidence of amyloid deposition
  • Determined by the investigator to be unsuitable for this type of study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03040713

Layout table for location information
United States, California
Movement Disorder Center, UCSD
La Jolla, California, United States, 92037
Memory and Aging Center, UCSF
San Francisco, California, United States, 94158
United States, Texas
UT Southwestern Medical Center
Dallas, Texas, United States, 75390
Sponsors and Collaborators
Avid Radiopharmaceuticals
Layout table for investigator information
Study Chair: Chief Medical Officer Avid Radiopharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Avid Radiopharmaceuticals Identifier: NCT03040713    
Other Study ID Numbers: 18F-AV-1451-A19
First Posted: February 2, 2017    Key Record Dates
Last Update Posted: January 10, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Frontotemporal Dementia
Aphasia, Primary Progressive
Pick Disease of the Brain
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Neurodegenerative Diseases
Proteostasis Deficiencies
Metabolic Diseases
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms